Business Context and Reporting Period
Company: Baxter International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2001
Business Overview: Baxter operates in three primary segments: Medication Delivery, BioScience, and Renal. The company manufactures and sells distinct products including intravenous infusion pumps, biopharmaceuticals, blood-collection products, and dialysis services.
Key Financial Metrics
| Metric (in millions) | Q1 2001 | Q1 2000 |
|---|---|---|
| Net Sales | $1,757 | $1,583 |
| Operating Income | $313 | $284 |
| Net Income | $162 | $191 |
| Diluted EPS | $0.54 | $0.65 |
| Cash and Equivalents | $723 | $694 |
| Total Debt (Short-term + Long-term) | $2,749 | N/A |
| Net Debt-to-Capital Ratio | 39.5% | N/A |
| Operational Cash Flow | ($111) Outflow | ($159) Outflow |
Note: Net Income for Q1 2001 includes a one-time cumulative effect of an accounting change (SFAS No. 133) reducing earnings by $52 million. Excluding this item, Net Income from continuing operations was $214 million.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% year-over-year. On a constant-currency basis, sales grew 16%, driven by strong performance in the BioScience and Medication Delivery segments.
- Profitability: Operating income rose 10% to $313 million. Gross profit margin improved to 43.9% from 43.4% due to a favorable product mix.
- Accounting Change: Adoption of SFAS No. 133 resulted in a $52 million reduction to net income, masking underlying operational growth.
- Acquisitions: Acquired Sera-Tec Biologicals, L.P. for approximately $127 million (paid in stock), adding 80 plasma centers to the BioScience segment.
- Segment Performance:
- Medication Delivery: Sales up 8%; Pretax income up 24%.
- BioScience: Sales up 16%; Pretax income up 5%.
- Renal: Sales up 9%; Pretax income down 13% due to higher R&D and marketing investments.
Guidance, Outlook, and Risks
- Management Outlook: Management expects gross profit margins to continue increasing and marketing/administrative expense ratios to decline for the remainder of 2001. R&D expenses are expected to remain at current levels.
- Stock Split: A 2-for-1 stock split was approved by the Board and shareholders, effective May 30, 2001.
- Legal Contingencies:
- Mammary Implants: Defendant in 563 lawsuits (approx. 1,104 plaintiffs) regarding silicone implants formerly manufactured by Heyer-Schulte. Management believes reserves are adequate, though future charges could impact net income.
- Plasma-Based Therapies: Ongoing litigation regarding HIV infections from factor concentrates (late 1970s-mid 1980s) and Hepatitis C from Gammagard(R) IVIG. Settlements are ongoing in the U.S. and Japan.
- Market Risks: Significant exposure to currency exchange rate fluctuations. A 10% unfavorable fluctuation in the U.S. Dollar could decrease the fair value of foreign exchange contracts by approximately $115 million.
Investor Verification Checklist
- Verify the impact of the $52 million SFAS No. 133 accounting charge on reported Net Income and EPS.
- Confirm the integration progress and revenue contribution of the Sera-Tec Biologicals acquisition.
- Monitor the status of mammary implant and plasma-based therapy litigation settlements and reserve adequacy.
- Assess the effect of the strengthening U.S. Dollar on future international sales growth.
- Review the timeline and execution of the 2-for-1 stock split.